(S1 (S (NP (CD Three) (JJ leading) (NN drug) (NNS companies)) (VP (VBD reported) (NP (JJ robust) (JJ third-quarter) (NNS earnings)) (, ,) (S (VP (VBN bolstered) (PP (IN by) (NP (NP (JJ strong) (NNS sales)) (PP (IN of) (NP (JJR newer) (, ,) (JJ big-selling) (NNS prescriptions) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP provide) (NP (JJ hefty) (NN profit) (NNS margins)))))))))) (. .)))

(S1 (S (S (NP (NNP Merck) (CC &) (NNP Co.)) (VP (VBD reported) (NP (NP (DT a) (ADJP (CD 25) (NN %)) (NN increase)) (PP (IN in) (NP (NNS earnings)))))) (: ;) (S (NP (NP (NNP Warner-Lambert) (NNP Co.) (POS 's)) (NN profit)) (VP (VBD rose) (NP (CD 22) (NN %)))) (CC and) (S (NP (NP (NP (NNP Eli) (NNP Lilly) (CC &) (NNP Co.)) (POS 's)) (JJ net) (NN income)) (VP (VBD rose) (NP (CD 24) (NN %)))) (. .)))

(S1 (S (NP (DT The) (NNS results)) (VP (VBD were) (PP (IN in) (NP (NP (NN line)) (PP (IN with) (NP (NP (NNS analysts) (POS ')) (NNS expectations)))))) (. .)))

(S1 (NP (NNP Merck) (CC &) (NNP Co) (. .)))

(S1 (S (NP (NP (NNP Merck)) (, ,) (NP (NP (NNP Rahway)) (, ,) (NP (NNP N.J.))) (, ,)) (VP (VBD continued) (S (VP (TO to) (VP (VB lead) (NP (NP (DT the) (NN industry)) (PP (IN with) (NP (NP (DT a) (JJ strong) (NNS sales) (NN performance)) (PP (IN in) (NP (DT the) (ADJP (JJ human) (CC and) (JJ animal)) (NNS health-products) (NN segment)))))))))) (. .)))

(S1 (S (NP (DT A) (JJR stronger) (NNP U.S.) (NN dollar)) (VP (VBD reduced) (NP (JJ third-quarter) (CC and) (JJ first-nine-month) (NNS sales) (NN growth)) (NP (QP (CD 2) (NN %) (CC and) (CD 3) (NN %))) (, ,) (ADVP (RB respectively))) (. .)))

(S1 (S (NP (JJ International) (NNS sales)) (VP (VBD accounted) (PP (IN for) (NP (NP (CD 47) (NN %)) (PP (IN of) (NP (JJ total) (NN company) (NNS sales))))) (PP (IN for) (NP (DT the) (CD nine) (NNS months))) (, ,) (PP (VBN compared) (PP (IN with) (NP (CD 50) (NN %)) (ADVP (NP (DT a) (NN year)) (RBR earlier))))) (. .)))

(S1 (S (NP (NP (NNS Sales)) (PP (IN for) (NP (DT the) (NN quarter)))) (VP (VBD rose) (PP (TO to) (NP (QP ($ $) (CD 1.63) (CD billion)))) (PP (IN from) (NP (QP ($ $) (CD 1.47) (CD billion))))) (. .)))

(S1 (S (S (NP (NP (NNP Mevacor)) (, ,) (NP (NP (NNP Merck) (POS 's)) (JJ new) (JJ cholesterol-lowering) (NN drug)) (, ,)) (VP (VBD had) (NP (NP (JJR higher) (NNS sales)) (SBAR (IN than) (S (NP (DT any) (JJ other) (NN prescription) (NN medicine)) (VP (VBZ has) (ADVP (RB ever)) (VP (VBN achieved) (PP (IN in) (NP (DT the) (NNP U.S.)))))))) (PP (IN in) (NP (DT the) (NN year))) (PP (VBG following) (NP (NN introduction))))) (, ,) (NP (DT the) (NN company)) (VP (VBD said)) (. .)))

(S1 (S (NP (DT The) (NN drug)) (VP (VBD was) (VP (VBN introduced) (PP (IN in) (NP (NNP West) (NNP Germany))) (NP (DT this) (NN year)))) (. .)))

(S1 (S (NP (NP (JJ Intense) (NN competition)) (PRN (, ,) (ADVP (RB however)) (, ,)) (VP (VBN led) (PP (TO to) (NP (NN unit) (NNS sales))))) (VP (VBZ declines) (PP (IN for) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NP (NNP Merck) (POS 's)) (JJ established) (ADJP (JJ human) (CC and) (JJ animal-health)) (NNS products)) (, ,) (PP (VBG including) (NP (NNP Aldomet) (CC and) (NNP Indocin)))))))) (. .)))

(S1 (S (PP (IN In) (NP (NNP New) (NNP York) (NNP Stock) (NNP Exchange) (JJ composite) (NN trading))) (NP (NN yesterday)) (, ,) (NP (NNP Merck) (NNS shares)) (VP (VBD closed) (PP (IN at) (NP ($ $) (CD 75.25))) (, ,) (ADVP (RB up) (NP (CD 50) (NNS cents)))) (. .)))

(S1 (NP (NNP Warner-Lambert) (NNP Co) (. .)))

(S1 (S (NP (NP (NNP Warner-Lambert)) (, ,) (NP (NP (NNP Morris) (NNP Plains)) (, ,) (NP (NNP N.J.))) (, ,)) (VP (VBD reported) (NP (NP (NP (NNS sales)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (NP (NP (DT a) (NN record)) (PP (IN for) (NP (DT any) (NN quarter)))))))) (CC and) (NP (NP (DT the) (JJ eighth) (NN quarter)) (PP (IN in) (NP (NP (DT a) (NN row)) (PP (IN of) (NP (QP (CD 20) (NN %) (CC or) (JJR more)) (JJ per-share) (NNS earnings) (NN growth)))))))) (. .)))

(S1 (S (S (VP (VBN Spurred) (PP (IN by) (NP (NP (NN growth)) (PP (IN in) (NP (NP (JJ world-wide) (NNS sales)) (PP (IN of) (NP (NP (DT the) (NN company) (POS 's)) (NN prescription) (NNS drugs))))))))) (, ,) (NP (NNP Warner-Lambert)) (VP (VBD said) (SBAR (S (NP (CD 1989)) (VP (MD will) (VP (VB be) (NP (NP (DT the) (JJS best) (NN year)) (PP (IN in) (NP (PRP$ its) (NN history)))) (, ,) (SBAR (IN with) (S (NP (JJ per-share) (NNS earnings)) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (QP (JJR more) (IN than) (CD 20)) (NN %)) (PP (TO to) (NP (QP (RB about) ($ $) (CD 6.10))))))))))))))) (. .)))

(S1 (S (NP (NP (NNS Sales)) (PP (IN for) (NP (DT the) (NN quarter)))) (VP (VBD rose) (PP (TO to) (NP (QP ($ $) (CD 1.11) (CD billion)))) (PP (IN from) (NP (QP ($ $) (CD 1.03) (CD billion))))) (. .)))

(S1 (S (S (NP (JJ Prescription-drug) (JJ world-wide) (NNS sales)) (VP (VBD rose) (NP (CD 9) (NN %)) (PP (IN in) (NP (DT the) (NN quarter))) (PP (TO to) (NP (QP ($ $) (CD 340) (CD million)))))) (: ;) (S (NP (NNP U.S.) (NNS sales)) (VP (VBD rose) (NP (CD 15) (NN %)))) (. .)))

(S1 (S (NP (NP (DT The) (NN segment) (POS 's)) (NN growth)) (VP (VBD was) (VP (VBN led) (PP (IN by) (NP (NP (NNS sales)) (PP (IN of) (NP (NP (DT the) (JJ cardiovascular) (NNS drugs)) (NP (NP (NP (NNP Lopid)) (, ,) (NP (DT a) (JJ lipid) (NN regulator)) (, ,)) (CC and) (NP (NP (NNP Dilzem)) (, ,) (NP (DT a) (NN calcium) (NN channel) (NN blocker)))))))))) (. .)))

(S1 (S (S (NP (NP (JJ World-wide) (NNS sales)) (PP (IN of) (NP (NP (NP (NNP Warner-Lambert) (POS 's)) (JJ non-prescription) (NN health-care) (NNS products)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNS Halls)) (NX (NX (NN cough) (NNS tablets)) (, ,) (NX (NNP Rolaids) (NN antacid)) (, ,) (CC and) (NX (JJ Lubriderm) (NN skin) (NN lotion))))) (, ,)))) (VP (VBD increased) (NP (CD 3) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 362) (CD million)))) (PP (IN in) (NP (DT the) (JJ third) (NN quarter))))) (: ;) (S (NP (NNP U.S.) (NNS sales)) (VP (VBD rose) (NP (CD 5) (NN %)))) (. .)))

(S1 (S (NP (NN Confectionery) (NNS products) (NNS sales)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJ strong) (NN growth)) (PP (IN in) (NP (DT the) (NN quarter))))) (. .)))

(S1 (S (NP (NP (NP (JJ World-wide) (NNS sales)) (PP (IN of) (NP (NNP Trident) (NN gum)))) (, ,) (NP (NNP Certs) (NN breath) (NNS mints)) (, ,) (CC and) (NP (JJ Clorets) (NN gum) (CC and) (NN breath) (NNS mints)) (, ,)) (VP (VBD increased) (NP (CD 12) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 277) (CD million))))) (. .)))

(S1 (S (NP (NNP Warner-Lambert) (NNS shares)) (VP (VBD closed) (PP (IN at) (NP (NP ($ $) (CD 109.50)) (NP (DT a) (NN share)))) (, ,) (ADVP (RB up) (NP ($ $) (CD 1.50))) (, ,) (PP (IN in) (NP (NNP Big) (NNP Board) (JJ composite) (NN trading))) (NP (NN yesterday))) (. .)))

(S1 (NP (NNP Eli) (NNP Lilly) (CC &) (NNP Co) (. .)))

(S1 (S (NP (NNP Lilly)) (VP (VBD attributed) (NP (NN record) (JJ third-quarter) (CC and) (JJ nine-month) (NNS results)) (PP (TO to) (NP (NP (JJ world-wide) (NNS gains)) (PP (IN for) (NP (NP (NNS pharmaceuticals)) (, ,) (NP (JJ medical) (NNS instruments)) (CC and) (NP (JJ plant-science) (NNS products)))))) (PP (IN despite) (NP (NP (JJ poor) (NN exchange) (NNS rates)) (PP (IN for) (NP (DT the) (NN dollar))) (SBAR (WHNP (WDT that)) (S (VP (VBD slowed) (NP (NP (NNS sales)) (ADVP (RB abroad))))))))) (. .)))

(S1 (S (NP (NNS Earnings)) (VP (VBD continued) (S (VP (TO to) (VP (NN pace) (NP (NNS sales)) (PP (IN because) (IN of) (NP (NP (DT a) (JJR lower) (NN tax) (NN rate)) (, ,) (NP (NP (NN profit)) (PP (IN from) (NP (NP (DT the) (NN renegotiation)) (PP (IN of) (NP (DT the) (NN debt) (NN instrument))) (VP (VBN received) (PP (IN from) (NP (NP (NNP Faberge) (NNP Inc.)) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (NP (NP (NNP Lilly) (POS 's)) (NN sale)) (PP (IN of) (NP (NP (NNP Elizabeth) (NNP Arden) (NNP Inc.)) (PP (IN in) (NP (CD 1987))))))))))))))) (, ,) (CC and) (NP (NP (JJ net) (NNS proceeds)) (PP (IN from) (NP (NP (DT the) (NN settlement)) (PP (IN of) (NP (NP (NN patent) (NN litigation)) (PP (IN at) (NP (NP (NNP Lilly) (POS 's)) (NNP Hybritech) (NNP Inc.) (NN unit)))))))))))))) (. .)))

(S1 (S (NP (NP (JJ Third-quarter) (NNS sales)) (PP (IN of) (NP (DT the) (NAC (NNP Indianapolis) (, ,) (NNP Ind.) (, ,)) (NN company)))) (VP (VBD rose) (NP (CD 11) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 1.045) (CD billion)))) (PP (IN from) (NP (QP ($ $) (CD 940.6) (CD million))))) (. .)))

(S1 (S (NP (JJ Nine-month) (NNS sales)) (VP (VBD grew) (NP (CD 12) (NN %)) (PP (TO to) (NP (QP ($ $) (CD 3.39) (CD billion)))) (PP (IN from) (NP (QP ($ $) (CD 3.03) (CD billion))) (ADVP (NP (DT a) (NN year)) (RBR earlier)))) (. .)))

(S1 (S (NP (NP (NNS Sales)) (PP (IN of) (NP (NP (NNP Prozac)) (, ,) (NP (DT an) (NN anti-depressant)) (, ,)))) (VP (VBD led) (NP (NNS drug-sales) (NNS increases))) (. .)))

(S1 (S (S (NP (NP (JJR Higher) (NNS sales)) (PP (IN of) (NP (NP (NNS pesticides)) (CC and) (NP (JJ other) (NN plant-science) (NNS products))))) (VP (ADVP (RBR more) (IN than)) (VBD offset) (NP (NP (DT a) (JJ slight) (NN decline)) (PP (IN in) (NP (NP (DT the) (NNS sales)) (PP (IN of) (NP (JJ animal-health) (NNS products)))))) (S (VP (TO to) (VP (VB fuel) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (JJ world-wide) (JJ agricultural) (NN product) (NNS sales))))))))) (, ,) (NP (NNP Lilly)) (VP (VBD said)) (. .)))

(S1 (S (NP (NP (NNP Advanced) (NNP Cardiovascular) (NNPS Systems) (NNP Inc.)) (CC and) (NP (JJ Cardiac) (NNS Pacemakers))) (NP (NNP Inc.) (NNS units)) (VP (VBD led) (NP (NP (NN growth)) (PP (IN in) (NP (DT the) (JJ medical-instrument) (NNS systems) (NN division))))) (. .)))

(S1 (S (NP (NNP Lilly) (NNS shares)) (VP (VBD closed) (NP (NN yesterday)) (PP (IN in) (NP (NP (JJ composite) (NN trading)) (PP (IN on) (NP (DT the) (NNP Big) (NNP Board))))) (PP (IN at) (NP ($ $) (CD 62.25))) (, ,) (ADVP (RB down) (NP (CD 12.5) (NNS cents)))) (. .)))

